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Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer death, has a 5-
year survival rate of approximately 7–9%. The ineffectiveness of anti-PDAC therapies is
believed to be due to the existence of a subpopulation of tumor cells known as cancer stem
cells (CSCs), which are functionally plastic, and have exclusive tumorigenic, chemoresistant
and metastatic capacities. Herein, we describe a 2D in vitro system for long-term enrichment
of pancreatic CSCs that is amenable to biological and CSC-specific studies. By changing the
carbon source from glucose to galactose in vitro, we force PDAC cells to utilize OXPHOS,
resulting in enrichment of CSCs defined by increased CSC biomarker and pluripotency gene
expression, greater tumorigenic potential, induced but reversible quiescence, increased
OXPHOS activity, enhanced invasiveness, and upregulated immune evasion properties. This
CSC enrichment method can facilitate the discovery of new CSC-specific hallmarks for future
development into targets for PDAC-based therapies.
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The past decade has seen great progress in the diagnosis andtreatment of different cancers; however, the same cannotbe said for pancreatic ductal adenocarcinoma (PDAC),
which is currently the fourth most frequent cause of cancer-
related death and projected to become the second most lethal
tumor by the year 20301. At the time of diagnosis, <20% of
patients present with localized (and thus potentially resectable
and curative) disease, 15–20% of patients have locally advanced
(unresectable) tumors, and the remaining patients present with
metastatic disease. To compound the situation further, even the
strongest chemotherapeutic regimens only extend overall survival
to approximately 11 months and very rarely result in long-term
progression-free survival (>5 years)2. Thus radically new
approaches are needed to identify novel and more effective
therapies for PDAC.
To achieve the latter, it is important to appreciate that pan-
creatic tumors are comprised of a heterogeneous population of
cancer cells with diverse replicative, tumorigenic, metastatic, and
chemoresistant capacities. Specifically, highly plastic sub-
populations of stem-like cells within the tumor, known as cancer
stem cells (CSCs), have been described for PDAC and are now
accepted to be the drivers of tumorigenesis, chemoresistance, and
metastasis3. Using CSC surface markers or three-dimensional
(3D) spheroid cultures to isolate pancreatic CSCs (PaCSCs), we
have advanced our ability to study and molecularly characterize
these cells. For example, we now appreciate that PaCSCs are
highly plastic and therefore have the capacity to alter their
metabolism, induce quiescence, resist chemotherapeutic insults,
and even evade the immune system by upregulating immune
evasion receptors or checkpoint inhibitors4. While much pro-
gress has been made, we are still far from completely under-
standing the complex biological makeup of PaCSCs, largely due
to the inability to establish long-term two-dimensional (2D)
cultures enriched in CSCs that are amenable to characterization
and screening studies.
Approaches that use specific signaling mechanisms to enrich
and maintain CSC subpopulations with phenotypic plasticity in
culture5 could prove useful for (1) dissecting the underlying
drivers of their plasticity and for (2) identifying new anti-CSC
targets for drug development. Toward this end, and based on our
previous work demonstrating the metabolic differences that exist
between PaCSCs and non-PaCSCs, we describe herein a long-
term and sustained cell culture system enriched in PaCSCs based
on forced oxidative phosphorylation (OXPHOS), defined by
electron transport chain+ATP synthase. In this culture system,
cells increase the expression of PaCSC biomarkers and present
better metabolic adaptation, plastic features such as a reversible
quiescence-like state, and CSC-associated phenotypes, including
chemoresistance, invasiveness, and immune evasive properties.
This culture method not only sheds light on the link between
previously unrecognized CSC features and mitochondrial-
dependent metabolism but also represents a platform that could
facilitate the discovery of CSC-specific properties that could lead
to the development of new therapies against PaCSCs, which could
ultimately improve the life expectancy of PDAC patients.
Results
PaCSCs have increased mitochondrial function. While 3D
anchorage-independent spheres allow for CSC enrichment, they
are not highly adaptable to various screening methodologies due
to their non-adherent 3D nature and need for serial passaging
once they reach critical mass. Attempts to establish 2D cultures
enriched in CSCs using fluorescence-activated cell sorter (FACS)
approaches have also proven ineffective as marker-enriched CSCs
quickly re-establish the heterogeneity of the culture present prior
to sorting. Thus the enrichment in PaCSCs is not a stable
phenotype and marker-enriched [CD133 and autofluorescence
(Fluo)6,7] CSCs quickly return to their pre-sort distribution
within 2–3 days post sorting (Fig. 1a). For these reasons, we
decided to further dissect CSCs to discover other properties that
could facilitate a long-term CSC-enriched 2D culture. Using
the classical PaCSC biomarker CD133, we divided PaCSCs
(CD133+) from non-PaCSCs (CD133−) and carried out a
transmission electron microscopy (TEM)-based analysis and
observed morphological and structural difference in their mito-
chondria. CD133+ cells (PaCSCs) contained more differentiated
mitochondria compared to CD133− cells (non-PaCSCs), which
exhibited swollen mitochondria with less pronounced cristae and
which appeared to be eliminated by autophagy (Fig. 1b). To
validate these observations, PaCSCs were sorted and marked with
probes for mitochondrial mass/membrane potential (MTDR and
MT-CMXRos). We observed that CD133+Fluo+ cultures showed
a significant increase in MTDR of ~3–4-fold and a significant
increase in MT-CMXRos of ~2–3-fold compared to CD133−
Fluo− cells (Fig. 1c–e). Quantification of the mitochondrial 12S
ribosomal RNA gene (MT-RNR1) also revealed a significant
increase in the number of mitochondrial DNA (mtDNA) copy
numbers in the CD133+Fluo+ population (Fig. 1f). These data
confirmed previous studies showing that PaCSCs have a more
active mitochondrial state8,9, which we reasoned could be
exploited to establish a long-term CSC-enriched 2D culture.
Toward this end, we used 5 mM galactose as an alternate carbon
source in our culture medium. Compared to 5 mM glucose, ATP
yield from 5mM galactose is slower due to the fact that the
conversion of galactose to glucose 6-phosphate requires several
more limiting enzymatic steps (Leloir pathway)10, and as shown
by Warburg in 1925, cancer cells use 18-fold less glycolysis when
galactose, in lieu of glucose, is provided as a sugar source11. Thus
galactose, together with exogenous mitochondrial OXPHOS
substrates (i.e., pyruvate and glutamine) leads to a compensatory
upregulation of OXPHOS12. As a consequence, cells that are
dependent on glycolysis but not on OXPHOS function (non-
PaCSCs) cannot survive in galactose, while cells that have an
efficient OXPHOS system (PaCSCs) will survive and become
enriched (Fig. 1g).
Galactose-cultured cells are enriched in PaCSCs. First, using the
IncuCyte Zoom System we performed a real-time analysis of the
CSC marker autofluorescence and cell confluency for PANC185
cells during 40 h of culture in glycolytic-restrictive conditions
(e.g., galactose). Interestingly, relative confluency was static and
did not change in galactose-cultured cells (Gal-CC) compared to
glucose-cultured cells (Gluc-CC) (Fig. 2a), but the ratio of the
CSC autofluorescent biomarker/relative confluency increased ~2-
fold in Gal-CC (Fig. 2b), indicating an enrichment in the CSC
population. Enrichment in autofluorescence and reduction in cell
confluency (i.e., proliferation) was more pronounced at longer
times (14 days) (Supplementary Fig. 1a, b), and coincided with
increased apoptosis in Gal-CC versus Gluc-CC across 4 PDAC
cell lines (Supplementary Fig. 1c), indicating that the observed
enrichment in PaCSCs was likely a consequence of cell death and
inhibition of cell proliferation. To validate the observed enrich-
ment in PaCSCs, we performed an extensive flow cytometry-
based (Supplementary Fig. 1d) analysis using other CSC
biomarkers6,13. Importantly, we observed that autofluorescence,
CD133, and CD24 significantly increased by more than twofold
and CXCR4 and TEM8 significantly increased by threefold in 14-
day Gal-CC compared to Gluc-CC (Fig. 2c, d). Moreover, CD90
and SSEA-4, PaCSC biomarkers present only on PANC286
and PANC185scd, respectively, significantly increased by more
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than fourfold (CD90) or twofold (SSEA-4) in 14-day Gal-CC
(Supplementary Fig. 1e, f). Maximum enrichment in PaCSC
marker expression in Gal-CC was observed at 14 days and thus
this time point was used for all experiments presented here
onwards. Importantly, the levels of CSC biomarker enrichment in
Gal-CC versus Gluc-CC were greater than those obtained for
sphere versus adherent cultures (Supplementary Fig. 1g). Lastly,
long-term PaCSC-enriched Gal-CC could be established directly
from a freshly resected patient-derived xenograft (PDX) tumor
(Supplementary Fig. 1h, i), highlighting the translatability of these
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While the above results supported that cell death and
inhibition of cell proliferation in Gal-CC was responsible for
PaCSC enrichment, these data could not negate the additional
possibility that CSC biomarker-negative cells were converting
into CSC biomarker-positive cells and also contributing to the
observed enrichment in PaCSCs. To address the latter, a double
FACS was performed to obtain highly pure CD133- or
autofluorescent-negative cell populations, which were then
cultured in glucose- or galactose-containing media to assess the
plasticity of CSC biomarker-negative cells. Independent of the
carbon source, CSC biomarker-negative cells gave rise to CSC
biomarker-positive cells, confirming previous observations
regarding plasticity of non-CSCs (Supplementary Fig. 2a, b).
However, at times >4 days post-sorting, a sharp decrease in the
percentage of CSC biomarker-positive cells was observed in Gluc-
CC, while in Gal-CC the percentages either remained constant or
increased, and at day 11 were ~2-fold higher than Gluc-CC
(Supplementary Fig. 2a, b), indicating that galactose culture
conditions potentiate and maintain plasticity. Importantly, this
fold difference coincided with an ~2-fold decrease in cell viability
in Gal-CC, confirming that PaCSC enrichment also coincides
with non-PaCSC cell death (Supplementary Fig. 2c). Importantly,
when CD133+ sorted cells were directly cultured in galactose, cell
viability was not negatively affected (Supplementary Fig. 2d).
Taken together, we concluded that in galactose-containing media
(1) PaCSCs survive, (2) a large percentage of non-PaCSCs die,
and (3) a smaller percentage of non-PaCSCs convert into
PaCSCs. The sum of these biological consequences results in a
PaCSC-enriched culture.
Gal-CC contain functional PaCSCs. We next characterized Gal-
CC at the molecular and functional level to confirm an enrich-
ment in PaCSCs. First, we measured self-renewal capacity and
observed significantly increased sphere-forming capacity for Gal-
CC compared to Gluc-CC (Fig. 2e), although spheres from Gluc-
CC were consistently larger (Fig. 2f). This increase over two
generations mirrors what is seen when PaCSCs sorted for CD133
are placed in sphere-formation conditions (Supplementary
Fig. 2e). Of note, we confirmed that the observed increase in self-
renewal capacity in Gal-CC was due to an enrichment in the
percentage of CSCs by showing that the percentage of
autofluorescent-positive (Fig. 2g) and CD133+CXCR4+ double-
positive (Fig. 2h) cells were significantly higher in Gal-CC (more
than threefold) compared to Gluc-CC in first- and second-
generation spheres. At the transcriptional level, and similar to
what is observed when PaCSCs are enriched using sphere for-
mation (Supplementary Fig. 2f), genes related to stemness (e.g.,
SOX9) and pluripotency (e.g., NANOG) were significantly
increased 2–3-fold in Gal-CC compared to Gluc-CC (Fig. 2i). The
latter was validated using a NANOG-YFP reporter system, in
which Yellow Nano-lantern (YNL) expression (indicative of
hNANOG promoter activity) was significantly higher in Gal-CC
compared to Gluc-CC (Fig. 2j). Recent evidence suggests that
different types of non-coding RNAs, such as long non-coding
RNAs (lncRNAs), also play a role in regulating CSC growth and
replication during cancer growth and metastasis14,15. Analysis of
the expression levels of a subset of lncRNAs revealed a significant
2–3-fold increase in their expression in Gal-CC compared to
Gluc-CC (Supplementary Fig. 1g), similar to our previously
published data using adherent and sphere cultures16.
As tumorigenesis is a hallmark of CSCs, an in vivo extreme
limiting dilution assay (ELDA) was performed using mCherry-
H2B-labeled Gal-CC and Gluc-CC. While the size, weight, and
percentage of mCherry-H2B+ Gluc-CC-derived tumors were
slightly greater or equal to those of the Gal-CC-derived tumors
(Supplementary Fig. 2h–l), tumor incidence for galactose-derived
cells was significantly higher at all dilutions tested (Fig. 2k).
Moreover, the percentage of CD133+ cells inside the mCherry-
H2B+ cell population was significantly higher in the vast majority
of tumors derived from Gal-CC versus Gluc-CC (Fig. 2l),
indicating an expansion of the CSC compartment, which was
confirmed by calculating the CSC frequency (Fig. 2m): Gal-CC (1
in 10,075) versus Gluc-CC (1 in 51,521), and in line with the
frequencies achieved when using the CSC markers CD133 or
autofluorescence to separate PaCSCs from non-PaCSCs (Supple-
mentary Fig. 2m). Taken together, the sum of these data indicates
that there exists an enrichment in CSCs when cells are cultured in
conditions that demand OXPHOS.
PDAC cells increase OXPHOS in the presence of galactose. We
previously published that PaCSCs use OXPHOS to meet their
energy requirements8. Likewise, Viale et al. showed that CSC-like
cells that resist oncogene ablation in PDAC murine models rely
on OXPHOS for their survival17. Since Gal-CC should be more
OXPHOS permissive, mitochondrial metabolism, markers of
mitochondrial mass/membrane potential and reactive oxygen
species (ROS) were analyzed (Fig. 3a). In line with our approach,
all markers significantly increased in Gal-CC (Fig. 3b), suggesting
increased OXPHOS and ROS production. Since some of the
aforementioned probes depend on membrane potential, we
additionally tested MitoTracker Green and Nonyl Acridine
Orange (NAO) and observed a similar significant increase in
mitochondrial mass (Supplementary Fig. 3a, b). To functionally
validate these findings, we measured the oxygen consumption
rates (OCRs) of Gluc-CC and Gal-CC (Fig. 3c). Baseline OCR was
significantly higher in Gal-CC compared to Gluc-CC, and both
Fig. 1 PaCSCs have increased mitochondrial function. a Primary cultures of PANC185 cells were sorted using the CSC markers CD133 or autofluorescence
(Fluo), and the percentage of CD133+ (black) or Fluo+ (purple) cells was re-determined by flow cytometry at the indicated hours post sorting (n= 3
biological replicates). b PANC185 cells were stained with an anti-CD133-APC antibody and sorted to divide the cell population into CD133− cells (non-
CSCs) and CD133+ cells (CSCs). Transmission electron micrographs were acquired and shown are representative images. Mitochondria (black arrow) are
better defined in the CD133+ population compared to CD133−, which present autophagosomes (white arrow) in their cytoplasm. c PDAC cultures were
sorted using two different CSC biomarkers, CD133 and autofluorescence (Fluo) to select two cell populations: CD133−Fluo− cells (non-CSCs) and CD133+
Fluo+ cells (CSCs). Five days post re-seeding, both populations were marked with the mitochondrial markers MitoTracker-DeepRed FM (red) and
Mitotracker-CMXRos (green), and DAPI (nuclear marker, blue). Shown are representative fluorescent images obtained by confocal microscopy analysis
for PANC185. d, e Quantification of the percentage of mean fluorescent area ± sd for the d MitoTracker-DeepRed FM mitochondrial biomarker or the
e Mitotracker-CMXRos mitochondrial membrane potential marker in PANC185 and PANCA6L, using ImageJ (n= 4 independent fields; Holm–Sidak t test
statistical analysis). DeepRed ***p= 0.00004; *p= 0.013 and CMXRos ***p= 0.00045; **p= 0.0028. f Quantification of mean relative mRNA expression
levels ± sd of the mitochondrial 12S ribosomal RNA gene (MT-RNR1) by qPCR in CD133+Fluo+ cells and CD133−Fluo− cells in PANC185 and PANCA6L
(n= 6 biological replicates or n= 12 biological replicates for Pooled data; Holm–Sidak t test statistical analysis). Data were normalized to β-actin expression
and presented as fold change for each tumor and pooled data. CD133−Fluo− was set as 1.0. ***p < 0.000001; ***p= 0.000001; ***p < 0.000001.
g Schematic representation of the Warburg and OXPHOS metabolism present in glucose and galactose culture conditions.
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the maximal respiration and the spare respiratory capacity (SRC)
significantly increased in Gal-CC compared to Gluc-CC (Fig. 3c,
d), indicating increased OXPHOS. Proton leak was also sig-
nificantly higher in Gluc-CC, indicating decreased mitochondrial
efficiency (Fig. 3d). As expected, extracellular acidification rate
(ECAR) revealed more acidification by glucose fermentation in
Gluc-CC compared to Gal-CC (Supplementary Fig. 3c), high-
lighting that OXPHOS is preferentially used over glycolysis in
Gal-CC. While direct confirmation of increased carbon flux into
the mitochondria (i.e., tricarboxylic acid cycle) would need to be




















End point: week 10
10,000 cells/injection
End point: week 10
5000 cells/injection
End point: week 10
1000 cells/injection



































































































































































































Gluc first generation Gluc second generation























50,000 10,000 5000 1000
Gluc
Gal
















































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18954-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5265 | https://doi.org/10.1038/s41467-020-18954-z | www.nature.com/naturecommunications 5
validated by liquid chromatography–mass spectrometry- or
nuclear magnetic resonance-based metabolomics, we indirectly
confirmed the latter by enzyme-linked immunosorbent assay
(ELISA) analysis of lactate production (Supplementary Fig. 3d).
At the level of total ATP, no significant differences were observed
between Gluc-CC and Gal-CC at the time point examined
(Supplementary Fig. 3e), which reflects differences in the kinetics
of ATP production and/or consumption or glycolytic rate com-
pensations between Gluc-CC and Gal-CC18.
Transcription of genes related to mitochondrial activity and
electron transport chain complexes (NDUFA9-Complex I and
MT-COI-Complex IV) and mitochondrial 16S ribosomal RNA
gene (MT-RNR2) also significantly increased in Gal-CC (Fig. 3e).
Importantly PGC1α, a key regulator of energy metabolism that
stimulates mitochondrial biogenesis, promotes OXPHOS meta-
bolism, and is overexpressed in PaCSCs8, was transcribed to
significantly higher levels in Gal-CC. Moreover, NRF2 and
PARKIN, related to the regulation of antioxidant proteins19 and
recycling of mitochondria via the coordinated process of mito-
fusion, mito-fission, and mitophagy20, were also significantly
increased (Fig. 3e). Analysis of MT-RNR1 DNA levels revealed
increased mtDNA copy numbers in Gal-CC compared to Gluc-
CC (Fig. 3f), consistent with more mitochondrial biogenesis. In
line with the latter, we observed a significant increase in the
percentage of MTDR and MT-CMXRos fluorescent area in Gal-
CC compared to Gluc-CC (Fig. 3g–i). Interestingly, we could
observe that the cells on the borders of the clones showed more
intense staining (Supplementary Fig. 3g), which could suggest a
greater energy demand, perhaps necessary for a higher duplica-
tion rate or migration21,22. The mitochondria of Gal-CC were
visually denser (Fig. 3g), and immunofluorescence (IF) analysis
revealed a significant increase in TOM20 staining (~2-fold) in
Gal-CC (Fig. 3j, k), which was also used to show that the
mitochondrial network in Gal-CC was more extensive compared
to Gluc-CC (Supplementary Fig. 3f). In addition, we observed
greater expression of PARKIN by flow cytometric analysis
(Supplementary Fig. 3h, i) and by IF (Fig. 3j, l) in Gal-CC,
indicating increased mitochondrial recycling.
Cell cycle and quiescence in Gal-CC. To dissect Gal-CC and
Glu-CC at the transcriptional level, we performed RNAseq ana-
lysis to identify differentially regulated pathways. In line with an
enrichment in PaCSCs, numerous CSC-associated pathways were
enriched in Gal-CC, such as mammalian target of rapamycin C1
(mTORC1), hypoxia, phosphoinositide-3 kinase/AKT/mTOR,
interleukin-6 (IL-6)/Janus-activated kinase/signal transducer and
activator of transcription factor 3 (STAT3), IL-2/STA5, and Wnt-
β-catenin signaling (Fig. 4a and Supplementary Fig. 4a). In
addition, and as a validation our OCR results and metabolic
analyses, OXPHOS was significantly enriched in Gal-CC (Fig. 4a
and Supplementary 4a). Finally, we observed a significant
reduction in G2/M checkpoint genes and E2F targets (Fig. 4a and
Supplementary 4b), including CDK1, which controls entry into
mitosis, the phosphatase CDC25A that controls entry into and
progression through mitosis and S phase, and principal regulators
of the mitotic checkpoint, including MAD2L1 and BUB1B23,24.
Based on these RNAseq data and our IncuCyte Zoom System
analysis (Fig. 1a, b), where we observed less proliferation in Gal-
CC, we performed a propidium iodide (PI)-based cell cycle
analysis. As expected, we measured a higher percentage of cells in
G0/G1 and S phases in Gal-CC, whereas more cells were in G2/M
phase in Gluc-CC (Fig. 4b), which is in line with cell cycle
inhibition and the idea that CSCs have a slower cell cycle,
resembling a quiescent-like state, compared to non-CSCs. To
discard whether senescence was affecting cell proliferation, β-
galactosidase activity was assessed (Fig. 4c), but the percentage of
β-galactosidase-positive area was significantly lower (twofold) in
Gal-CC compared to Gluc-CC (Fig. 4d), suggesting that Gal-CC
are less senescent. For this reason, we performed a quiescence
assay by labeling cultures with the red fluorescent plasma
membrane lipophilic dye PKH26 (Fig. 4e) to evaluate prolifera-
tion at different times (Fig. 4f). The percentage of PKH26+ cells
were very similar at 3 days (Fig. 4g–j); however, at 7 days a
significant reduction of >15% in the percentage of PKH26+ Gluc-
CC was observed, while the percentage of PKH26+ Gal-CC did
not significantly change (Fig. 4g–j). Finally, at 14 days, a
reduction of >50% in the percentage of PKH26+ Gluc-CC was
observed, whereas in Gal-CC the percentage of PKH26+ cells was
reduced only by 10–15% (Fig. 4g–j). To determine whether these
cultures were permanently fixed in a quiescent-like state,
galactose-containing medium was substituted for glucose-
containing medium, and in as little as 7 days, all of the Gal-CC
showed a significant reduction in the percentage of PKH26+ cells
(~80%) (Fig. 4k), indicating a reversal in the observed quiescent-
like state. Of note, this decrease was greater/faster than that
observed in Gluc-CC at 7 days (Fig. 4g–j).
Autophagy increases in Gal-CC. CSCs use autophagy to regulate
quiescence and self-renewal and have more autophagic flux to
help them better survive in stressful conditions (e.g., lack of
nutrients, hypoxia, and chemotherapeutics)25,26. By brightfield
microscopy, morphological differences between Gluc-CC and
Fig. 2 Gal-CC are enriched in PaCSCs. a Real-time quantification of cell confluence. b Quantification of mean ratio ± sd of the percentage of
autofluorescence/confluence at 40 h, extrapolated from the data acquired from the IncuCyte Zoom System. (n= 3 biological replicates; Holm–Sidak t test
statistical analysis). ***p= 0.00022. c Representative flow cytometric plots of the percentage of CSCs biomarkers. d Quantification of mean fold change ±
sd of CSCs biomarkers for 4 different tumors (biological replicates: n= 14 for autofluorescence; n= 6 for CD133; n= 7 for CD24, n= 10 for CXCR4; n= 4
for TEM8; Holm–Sidak t test statistical analysis). Gluc was set as 1.0. ***p < 0.000001; ***p= 0.00002; ***p < 0.000001; **p= 0.0067; **p= 0.0045.
e Mean number (no.) ± sd of first- and second-generation (gen) spheres/ml at 7 and 14 days (n= 6 biological replicates; Holm–Sidak t test statistical
analysis). ***p= 0.000025; *p= 0.043; **p= 0.0094; ***p= 0.00029. f Representative PANC185 sphere images at 14 days. Scale bar= 30 µM. g, h Flow
cytometric quantification of mean fold change ± sd of g autofluorescent-positive or h CD133+CXCR4+ cells detected in spheres at 7 and 14 days. Gluc
was set as 1.0. (n= 6 biological replicates; Holm–Sidak t test statistical analysis) For g: ***p= 0.0001; **p= 0.0036. For h: ***p= 0.0008; ***p= 0.0003.
i RT-qPCR analysis of relative mRNA expression levels of different pluripotency/stemness genes for 4 different tumors. Levels are normalized to β-actin
(n= 2 biological replicates for each tumor; Holm–Sidak t test statistical analysis). Data are presented as pooled mean fold change ± sd. Gluc was set as 1.0.
***p= 0.000017; **p= 0.0085; ***p= 0.000034; ***p= 0.00085; ***p < 0.000001. j Flow cytometric quantification of the mean percentage ± sd of
Nanog reporter YFP+ PANC185 cells at 14 days. (n= 5 biological replicates; Mann–Whitney t test statistical analysis). *p= 0.032. k Images of tumors
obtained at the time of sacrifice for an extreme limiting dilution assay with 1 × 103–5 × 104 mCherry-H2B PANCA6L Gluc-CC and Gal-CC. l Flow cytometric
quantification of mean of percentage ± sd of double-positive mCherry+CD133+ cells after digestion of Gluc-CC and Gal-CC tumors. Number (n) of samples
analyzed are indicated. (Holm–Sidak t test statistical analysis). *p= 0.044; ns= 0.066; **p= 0.0022.m Number of tumors obtained, the frequency (Freq),
and percentage (%) of CSCs present in tumors as a function of the dilutions tested.
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Gal-CC were observed (Fig. 5a), with Gal-CC forming smaller
and more compact clones with significantly more vacuolar bodies
in their cytoplasm than Gluc-CC (Fig. 5a). TEM analysis con-
firmed enrichment in electron-dense cellular structures, many
reminiscent of double membranes/multi-lammelar autophagic
vesicles27 in Gal-CC (Fig. 5b). Quantification of autophagic
vesicles revealed greater numbers in Gal-CC compared to Gluc-
CC (Fig. 5b, c). IF analysis of LC3B I–II and LAMP-1, both
essential proteins related to the autophagic process, revealed that
Gal-CC had a higher percentage of LC3B I–II and LAMP-1
fluorescent area compared to Gluc-CC (Fig. 5d, f), indicating both
increased autophagy and lysosome numbers. To confirm these
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results, we analyzed the basal levels of LC3B I and LC3B II by
western blotting (WB) analysis (Fig. 5g) and observed that the
levels of LC3B II increased in each PDAC culture in the presence
of galactose (Fig. 5h), as well as the expression of ATG5, a key
regulator of autophagy (Fig. 5i). To definitively confirm increased
autophagy in Gal-CC, we evaluated autophagic flux. After treat-
ment with Bafilomycin A1, a known inhibitor of the late phase of
autophagy, the levels of LC3B I and LC3B II were evaluated by
WB analysis (Fig. 5j), and a significant increase in the autophagic
flux was observed for Gal-CC (Fig. 5k).
Chemoresistance is enhanced in Gal-CC. Chemoresistance is an
inherent characteristic of PaCSCs, it is linked to increased
autophagy25,26, and overexpression of ATP-binding transporters
(ABC transporters), such as ABCG2, are known effectors of
chemoresistance across multiple tumor types6. In Gal-CC,
ABCG2 transcript levels significantly increased ∼2-fold compared
to Gluc-CC (Supplementary Fig. 5a). In addition, we evaluated
the expression of genes related to the transport of Gemcitabine
(GEM), one of the frequently used chemotherapeutics in the
treatment of PDAC, specifically the GEM efflux transporters
hENT1 and hENT228 and the GEM influx transporter CNT129.
CNT1 was significantly lower in Gal-CC compared to Gluc-CC,
whereas hENT1 and hENT2 were significantly higher (Supple-
mentary Fig. 5b). In view of these results, we next evaluated the
capacity of relapse/survival of the different Gluc-CC and Gal-CC
after treatment with different chemotherapeutics (Mitoxantrone
(MTX), Doxorubicin (DXR), and GEM; Supplementary Fig. 5c)
and observed significantly less cell death for all treatments and
across all PDAC cultures in the presence of galactose compared to
glucose (Supplementary Fig. 5d–f). While resistant to che-
motherapeutics, Gal-CC were highly sensitive to OXPHOS
metabolic drugs, such as Menadione, Rotenone, Resveratrol, and
Metformin, but not to the glycolytic irreversible inhibitor, 2-
deoxy-glucose (2-DG; Supplementary Fig. 5g–k).
Immune evasion properties are enriched in Gal-CC. Many
studies have also shown that there is a clear relationship between
quiescence and immune evasion mechanisms and metastasis4,30.
Since little is known about PaCSC immune evasion, we evaluated
the expression of ligands and receptors related to immune sup-
pression of T cells (programmed death-ligand 1 (PD-L1)); anti-
phagocytic function (CD47); and invasion, migration, and
metastasis (CD155 and CD206) and observed that all were sig-
nificantly upregulated in Gal-CC compared to Gluc-CC (Fig. 6a,
b). Interestingly, ULBP2/5/6 ligands related to the activation of
natural killer (NK) cell receptors were significantly down-
regulated in Gal-CC (Fig. 6a, b).
At the transcriptional level, we evaluated different
epithelial–mesenchymal transition (EMT)-related genes. ZEB1, a
key regulator of invasion and metastasis31, as well as the EMT
transcription factors (TF) SNAI2 and SNAI1 were significantly
higher in Gal-CC compared to Gluc-CC, whereas CDH1 and VIM
were unchanged (Fig. 6c). We next evaluated transforming
growth factor-β (TGFβ) secretion levels, one of the most
important cytokines implicated in stemness, EMT, and extra-
cellular matrix regulation, and measured significantly higher
levels in Gal-CC compared to Gluc-CC (Fig. 6d). We also found a
significant overexpression of nuclear factor-κB in Gal-CC, an
important TF that mediates cytokine secretion32 (Fig. 6e). Based
on this result, we performed a cytokine array. Overall, we found
differences in the levels of expression of different secreted
cytokines or inflammatory-associated molecules in both culture
conditions (Fig. 6f and Supplementary Fig. 6a, b). Significant
differences were found in C-C motif chemokine ligand 2 (CCL2),
C-X-C motif chemokine ligand 12 (CXCL12), granulocyte
macrophages colony-stimulating factor (GM-CSF), and soluble
intercellular adhesion molecule (ICAM)-1 (Fig. 6g), as well as
CCL5, CXCL1, Serpin E1, and IL-8 (Fig. 6h). Interestingly, the
factors that significantly increased in Gal-CC have been
associated with higher stemness (CCL2, IL-8); tumorigenesis
(CCL2, CXCL12, IL-8); chemoresistance (CXCL12); metastasis,
migration, and invasion (CXCL12, IL-8); and quiescence
(CXCL12). On the other hand, the decrease of the other factors
has been correlated with lower chemotaxis, communication and
activation of immune cells like T cells, basophils, neutrophils
(ICAM-1, CCL5, CXCL1), higher quiescence and infiltration of
pro-inflammatory macrophages (GM-CSF), higher metastasis,
and stemness (Serpin E1)33.
To test whether Gal-CC are more immunoevasive, we performed
functional in vitro immune evasion assays. Co-culturing DilC-
stained (red) macrophages from 3 healthy donors with PKH67-
stained (green) tumor cells (Glu- and Gal-CC) (Fig. 6i) resulted
in less double-positive DilC+PKH67+ cells (indicative of
macrophage-mediated phagocytosis) (Fig. 6j) for Gal-CC compared
to Gluc-CC (Fig. 6k), indicating that macrophages are less able to
detect and phagocytose Gal-CC than Gluc-CC, likely due to the
overexpression of the “don’t eat me” CD47 receptor34 on the surface
of Gal-CC (Fig. 6a, b). Next, activated T cells were co-cultured with
tumor cells (Glu- and Gal-CC). Regardless of the donor and PDAC
cell line used, T cells were less efficient at eliminating Gal-CC
Fig. 3 PDAC cells increase OXPHOS in the presence of galactose. a Representative flow cytometric histograms of the mean fluorescence intensity of cells
expressing the indicated markers. b Quantification of mean fold change ± sd of the different markers in a (n= 9 biological replicates; Holm–Sidak t test
statistical analysis). Gluc was set as 1.0. **p= 0.00107; ***p= 0.00007; ***p < 0.000001; ***p= 0.00027; **p= 0.0013. c Representative plot showing
mean ± sd of oxygen consumption rate (OCR) at the indicated times, normalized to cell number, which were treated with distinct inhibitors of
mitochondrial function: O (oligomycin), F (FCCP), A (antimycinA), and R (rotenone). Continuous OCR values (pmoles/min/cell) are shown. d Measured
and calculated mean ± sd OCR parameters (n= 3 biological replicates with 3 readings; Holm–Sidak t test statistical analysis). ***p= 0.000003; ***p <
0.000001; ns= 0.223; ***p < 0.000001; ***p= 0.0003; ***p= 0.0005. e RT-qPCR analysis of relative mRNA expression of different genes related to
mitochondrial activity and electron transport chain complexes and ROS neutralization. mRNA levels are normalized to β-actin (n= 8 biological replicates;
Holm–Sidak t test statistical analysis). Data are presented as fold change ± sd. Gluc was set as 1.0. **p= 0.0085; **p= 0.055; **p= 0.00103; ***p=
0.00032; *p= 0.018. f RT-qPCR analysis of mean relative mitochondrial 12S ribosomal RNA gene (MT-RNR1) levels for each PDAC culture and pooled
samples. Data are normalized to β-actin (n= 3 biological replicate; Holm–Sidak t test statistical analysis). Data are presented as fold change ± sd. Gluc was
set as 1.0. **p= 0.0017; *p= 0.03; **p= 0.0029; ***p= 0.000028. g Representative fluorescent images of Mitotracker DeepRed FM (red), CMXRos
(green), and DAPI (blue) staining. h, i Quantification of mean percentage of fluorescent area ± sd for h MitoTracker-DeepRed FM mitochondrial biomarker
or the i CMXRos mitochondrial membrane potential marker, using ImageJ. (n= 5 independent fields; Holm–Sidak t test statistical analysis). For h: **p=
0.0064; **p= 0.0073. For i: ***p= 0.000039; **p= 0.0083. j Representative immunofluorescent images of TOM20 (red), PARKIN (green), and DAPI
(blue) staining. k, l Quantification of mean percentage of fluorescent area ± sd for k TOM20 mitochondrial marker or l PARKIN, using ImageJ (n= 4
independent fields; Holm–Sidak t test statistical analysis). For k: ***p= 0.00054; **p= 0.0013. For l: ***p= 0.00012; ***p= 0.000099.
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compared to Gluc-CC when they were co-cultivated (Fig. 6l, n).
Importantly, the levels of cell death detected in T cell/Gal-CC co-
cultures was very similar to control cultures (without T cells) for
Donor 1 (Fig. 6l) and Donor 3 (Fig. 6n). T cells from Donor 2, in
general, displayed higher cytolytic capacity (Fig. 6m).
Upregulated in vivo immune evasion and metastasis in Gal-CC.
To functionally test the invasive capacity of Gal-CC and Gluc-CC,
zebrafish and NOD-SCID mouse models of cellular invasion were
employed. Zebrafish embryos were microinjected into circulation
(Duct of Cuvier), as previously described35. While at 1 day post-
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injection (dpi) PANCA6L mCherry-H2B Gluc-CC migrated
more efficiently to the tail compared to Gal-CC (Fig. 7a, b), Gluc-
CC were less viable at later time points, as evident by the loss in
fluorescence observed at 4 and 6 dpi (Fig. 7c, d). For
PANC185scd, similar results were observed (Supplementary
Fig. 6c–f). To extend these observations, NOD-SCID mice were
tail vein injected with Gluc-CC or Gal-CC and their capacity to
disseminate and invade to distant organs was assessed at 10 dpi
(short time) and 3 months pi (long time) (Fig. 7e).
At 10 dpi, while there was no significant increase in mCherry-
positive cells in the spleen, liver, or lungs, there was a significant
increase in the pancreas and blood in mice injected with Gal-CC
(Fig. 7f and Supplementary Fig. 7a). However, at 3 months pi, we
found that mice injected with Gal-CC presented with significantly
higher percentages of mCherry-positive cells in most organs
compared to mice injected with Gluc-CC, including the liver, one
of the main metastatic sites in PDAC patients (Fig. 7g and
Supplementary Fig. 7a). In some organs, such as kidneys, thymus,
and lymphatic nodes, no significant differences were observed
(Supplementary Fig. 7c). Results were confirmed and validated
ex vivo using IVIS imaging (Fig. 7h, i) or by immunohistochem-
ical (IHC) analysis of human cytokeratin-19 (Supplementary
Fig. 7a, b). Interestingly, we found numerous and abnormally large
lymphatic nodes in mice injected with Gal-CC, which were not
detected in the mice injected with Gluc-CC (Fig. 7h, yellow
squares). Lastly, we analyzed in each organ the percentage of
tumor-associated macrophages (TAMs) (CD45+CD11b+F4-80+),
which are known to play an important role both in the primary
tumor and for pre-metastatic niche formation. In mice injected
with Gal-CC, we observed at 10 dpi significantly lower TAMs in
the liver and pancreas (Fig. 7j); however, at 3 months pi the
population of TAMs increased significantly in all the organs
analyzed except the lungs and kidneys (Fig. 7k and Supplementary
Fig. 7d).
Discussion
We have developed a 2D in vitro system for long-term and
sustained enrichment of PaCSCs based on forced OXPHOS. By
culturing cells with galactose in lieu of glucose, cells that are
exclusively dependent on glycolysis (non-PaCSCs) cannot survive
due to differences in ATP yield and availability of glycolysis
intermediates. Indeed, we observed cell death in the presence of
galactose that coincided with an increase in the PaCSC popula-
tion, confirming that non-PaCSCs cannot survive in galactose. To
confirm the latter, we placed purified non-CSCs in galactose and
observed that, while galactose favors the conversion of non-
PaCSC in PaCSCs (i.e., plasticity), this contribution is secondary
compared to the enrichment achieved due to loss of the non-
PaCSC compartment. While we have not defined the mechanism
of non-PaCSC plasticity, it is plausible that non-PaCSCs could
increase their mitochondrial mass to survive in metabolically
restrictive conditions.
In our OXPHOS-promoting system, we observed a profound
increase in traditional CSC features, such as the expression of
multiple CSC biomarkers, overexpression of pluripotency-
associated genes and stem-related pathways (validated by RNA-
seq), increased NANOG promoter activity, enhanced self-renewal
capacity, and, most notably, significantly higher in vivo tumor-
igenicity. Other studies using alternate carbon sources (i.e.,
fructose) in breast cancer cells observed similar results but their
studies were not as exhaustive and did not evaluate all of the
phenotypes presented herein36. Not surprisingly, we did not
obtain 100% CSC biomarker staining in Gal-CC, which we
reconcile by acknowledging that heterogeneity exists within the
CSC population(s), making it impossible to detect all CSC clones
as not all CSCs (or OXPHOS-dependent hybrid CSCs) will
express the same single biomarker or combinations of different
biomarkers. Nonetheless, the increase observed in defined CSC
markers (>15%) and others (mitochondrial markers of approxi-
mately 100% and immune evasion markers of >50%) clearly
indicate an enrichment comparable to that obtained with tradi-
tional approaches6,7,13. Apart from traditional CSC features, we
also observed that Gal-CC were more slow cycling than Gluc-CC,
linking OXPHOS to a quiescent-like state, a feature typically
associated with a CSC’s survival and metastatic capacity4.
Importantly, the latter was not permanent and/or irreversible, as
Gal-CC are highly plastic and can exit this slow-cycling state in
accordance to the carbon source available. Whether OXPHOS
metabolism is favored by quiescent CSCs as a means of main-
taining mitochondrial membrane potential, ATP production, and
mtDNA content is still to be determined21.
Many studies have shown that slow-cycling/dormant tumor
cells are also more chemoresistant, have epithelial–mesenchymal
plasticity (EMP), and are better able to evade the immune system,
facilitating post-treatment relapse, tumor cell dissemination, and
survival in hostile environments37,38. Along these lines, Gal-CC
were more chemoresistant to a panel of traditional chemother-
apeutics, largely due to the overexpression of the ABCG2 trans-
porter and the different levels of expression of genes related to
GEM transport. In contrast, and as expected, Gal-CC were more
sensitive to OXPHOS metabolic drugs and less sensitive to the
glycolytic irreversible inhibitor 2-DG. Moreover, we also observed
increased autophagy in Gal-CC, suggesting that autophagy is also
likely an important mechanism used by OXPHOS-dependent
cells in metabolically restrictive conditions, such as those faced by
CSCs in the tumor microenvironment (TME) where oxygen and
nutrients are reduced. It has also been observed that autophagy is
strongly linked to quiescent/dormant processes in cancer
Fig. 4 CSC-specific pathways, including quiescence, are enriched in Gal-CC. a Gene sets enriched in the transcriptional profile of PANCA6L Gal-CC
compared with Gluc-CC. Shown are the NES (normalized enrichment score) values for each pathway using the Hallmark genesets, with nominal p value of
<0.05 and FDR < 25%. Stem-related pathways, metabolism pathways, and cell cycle pathways are color coded. b Cell cycle analysis of Gluc-CC and Gal-
CC PDAC cultures (PANC185, PANC185scd, and PANCA6L) determined by flow cytometric analysis using propidium iodide. c Representative brightfield
images by β-galactosidase staining of PANC185 Gluc-CC and Gal-CC (blue). Scale bar= 50 µM. d Quantification of mean percentage of positive area ± sd
of β-galactosidase in Gluc-CC and Gal-CC, using ImageJ (n= 6 independent fields; Holm–Sidak t test statistical analysis). ***p= 0.00027; ***p= 0.00021.
e Representative fluorescent images of PANC185 Gluc-CC and Gal-CC stained with PKH26 (red) at 14 days. Scale bar= 50 µM. f Representative flow
cytometric dot plots of the percentage of PKH26-positive cells in Gluc-CC and Gal-CC at different times (3, 7, and 14 days). g–j Quantification of mean
percentage ± sd of PKH26-positive cells at the indicated times (0, 3, 7, and 14 days) for Gluc-CC to Gal-CC (n= 3 biological replicates per culture;
Holm–Sidak t test statistical analysis). For g PANC185: ns > 0.99; ns= 0.09; ***p= 0.000078; ***p= 0.000033, for h PANC185scd: ns > 0.99; ns=
0.052; *p= 0.022; **p= 0.0023, for i PANCA6L: ns > 0.99; ns= 0.053; *p= 0.013; **p= 0.0052, and for j PANC286: ns > 0.99; *p= 0.019; **p=
0.0042; **p= 0.0038. k Quantification of mean percentage ± sd of PKH26-positive cells in Gal-CC after 14 days in galactose-containing media and 7 days
after substitution with glucose (n= 3 biological replicates; Holm–Sidak t test statistical analysis). ***p= 0.00003; ***p= 0.000057; ***p= 0.000002;
***p= 0.0003.
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cells39,40 as well as EMT and EMP. For example, two recent
reports demonstrate that autophagy is intimately linked to the
capacity of cancer cells to transition between epithelial and
mesenchymal states38,41. EMP is now considered a critical process
for tumor cell dissemination, metastatic colonization, and che-
moresistance. Not only were Gal-CC more chemoresistant but
also different EMT TFs were significantly overexpressed,
including ZEB1, which was recently linked to PDAC metabolic
plasticity in vivo42. In fact, biological associations between EMT
and metabolic reprogramming in cancer have been described and
shown to be a consequence of EMT TF signaling43. Thus the
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dependent CSCs is not surprising but does validate the system
and its biological relevance.
Finally, we show that OXPHOS-driven PaCSCs exhibit
immune evasive phenotypic and functional properties. Indeed,
studies have speculated that CSCs may maintain only limited
antigen-presentation levels and hence are invisible to the
immune system, but it is also possible that CSCs possess anti-
gen editing-independent capacities that may endow them with
immunoevasive properties5,33,44. In this sense, Gal-CC secreted
more TGFβ and acquired a previously uncharacterized immune
evasive molecular signature, enabling them to evade immune
innate cells (i.e., macrophages and NK cells) and immune
adaptive cells (T cells) thanks to the modulation of different
immune-associated receptors, ligands, and secreted cytokines.
As a consequence, Gal-CC were more invasive and metastatic
in vivo and were able to modulate the immune infiltrating cell
profile at early and late times post-injection, attracting fewer
immune cells during the early stages of extravasation, while at
later times promoting the accumulation of pro-tumor immune
cells, specifically TAMs, which facilitate establishment of the
niche and TME.
It is not surprising that mitochondria are important mediators
of tumorigenesis21. While we have previously shown that PaCSCs
use OXPHOS to meet their energy requirements8, herein we
expand upon this observation by showing that Gal-CC have a
denser and more extensive mitochondria network and have more
functional mitochondria compared to glycolytic cells (non-
PaCSCs). Indeed, Gal-CC overexpress mitochondrial-associated
genes, such as PGC1α, which promotes mitochondrial biogenesis
and OXPHOS and these processes are linked to cancer cell
migration, EMP, and immune evasion21. Likewise, it has been
shown in other systems that the aberrant expression of immune
evasion receptors (e.g., PD-L1) is metabolically controlled45, and
in cancer, correlations between metabolic alterations, EMT, and
PD-L1 upregulation have been demonstrated46. Thus our system
has allowed us to rigorously demonstrate that the metabolism of
PaCSCs is intimately linked to their stem, slow-cycling, meta-
static, and immunoevasive capacities.
Methods
Primary human PDAC cells. PDAC PDXs were obtained from Dr. Manuel Hidalgo
under a Material Transfer Agreement with the Spanish National Cancer Centre
(CNIO), Madrid, Spain (Reference no. I409181220BSMH) and were originally
described and genetically characterized in ref. 47. For primary cultures, PDX-derived
tumor tissue fragments were minced, enzymatically digested with collagenase (Cat no.
07416, Stem Cell Technologies) for 60min at 37 °C, and after centrifugation for 5min
at 500 × g the pellets were resuspended and cultured in RPMI, 10% fetal bovine serum
(FBS), and 50 units/ml penicillin/streptomycin as described previously7. PDAC PDX-
derived cultures are referred to by a random number designation [i.e., PANC185,
PANC185scd (single-cell-derived)7, PANCA6L, and PANC286]. Primary cultures
were tested for Mycoplasma at least every 4 weeks.
Establishment of OXPHOS-competent and -independent cultures. Low passage
(<15) PDX-derived primary PDAC cultures were trypsinized and seeded at a
concentration of 800,000 cells in p100 plates with RPMI medium supplemented
with 10% FBS and 50 units/ml of penicillin and streptomycin. After 24 h, cells were
cultured with either glucose-free Dulbecco’s Modified Eagle Medium (DMEM;
Thermo Fisher Scientific) supplemented with 5 mM glucose (0.9 g/l), 10% FBS, 50
units/ml of penicillin and streptomycin, and 1 mM of pyruvate [Glucose:
OXPHOS-independent conditions] or glucose-free DMEM medium (Thermo
Fisher Scientific) supplemented with 5 mM galactose (0.9 g/L), 10% FBS, 50 units/
ml of penicillin and streptomycin, and 1 mM of pyruvate [Galactose: OXPHOS-
competent enriched conditions]. Sugar concentrations of 5 mM were chosen to
mimic physiological sugar levels (glucose, 5 mM) and to avoid potential biological
artifacts mediated by supraphysiological sugar levels. Media for both conditions
were changed every day, over a period of 14 days, after which cells were collected
for further processing and analysis, as described below. Earlier time points (e.g.,
7 days) were also tested, but maximum levels of markers and gene expression were
obtained at 14 days, and thus this time point was chosen for all experiments
described herein. Gal-CC cultures can be maintained in culture indefinitely
(>70 days tested), trypsinized, and passaged if necessary, as well as cryopreserved
for future thawing and usage.
Flow cytometry and sorting. Cells were resuspended in Flow buffer [1×
phosphate-buffered saline (PBS); 3% FBS (v/v); 3 mM EDTA (v/v)] before analysis
with a 4-laser Attune NxT Acoustic Cytometer (Thermo Fisher Scientific). Cyto-
metry data were acquired with the Invitrogen™ Attune™ NxT software, version
3.1.1, unless specified otherwise. For cell surface marker expression, refer to anti-
bodies listed in Supplementary Table 1. For detection of PARKIN by cytometry,
cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min, washed, and
permeabilized for 15 min with 1% Triton X-100. For Annexin-V staining, floating
and attached cells were pooled and resuspended in 1× Annexin-V staining buffer
containing Annexin-V-fluorescein isothiocyanate (FITC) diluted 1:20 (Cat no.
29001, Biotium, Freemont, CA) and incubated for 20 min at room temperature
(RT) prior to flow cytometric analysis. For autofluorescent detection, cells were
excited with blue laser 488 nm and selected as intersection with the filters 530/40
(FITC) and 580/30 (phycoerythrin (PE))7. For all assays, 2 mg/ml 4,6-diamidino-2-
phenylindole (DAPI; Cat no. D9564, Sigma) was used to exclude dead cells with
laser VL1. Data were analyzed with the FlowJo 9.3 software (Tree Star Inc., Ash-
land, OR.). For cell sorting, cells were resuspended in sorting buffer [1× PBS; 0.1%
FBS (v/v); 3 mM EDTA (v/v)] and a FACS Vantage SE Flow Cytometer was used
and events were analyzed by the BD FACSDivaTM software v.9.0 (BD Biosciences,
San Jose, CA). Examples of gating strategies for all of the aforementioned
cytometry-based analyses are presented in Supplementary Fig. 1d.
For mitochondria markers, Gluc-CC and Gal-CC were stained with Mitotracker
Deep Red (Cat no. M22426), CM-H2XRos (Cat no. M7513), MitoTracker® Red
CMXRos (Cat no. M7512), Mitotracker Green FM (Cat no. M7514), and NAO
(Cat no. A1372) (all from Invitrogen) in the absence of FBS for 30 min at 37 °C, at
Fig. 5 Autophagy increases in Gal-CC. a Representative brightfield images of 14-day PANC185 Gluc-CC or Gal-CC, taken by optical microscopy. Scale bar
= 50 µM. b Representative transmission electron micrographs of 14-day PANC185 Gluc-CC or Gal-CC. Autophagic structures (red arrow heads). c Mean
number of autophagic vesicles ± sd in the TEM images of 14-day PANC185 and PANCA6L Gluc-CC and Gal-CC, quantified by ImageJ (n= 6 independent
fields; Holm–Sidak t test statistical analysis). **p= 0.0078; ***p= 0.00011. d Representative immunofluorescence images of PANC185 Gluc-CC and Gal-
CC stained with anti-LC3BI/II (green), anti-LAMP-1 (red), and DAPI (blue). e Mean percentage of fluorescent area ± sd for LC3BI/II comparing Gluc-CC
and Gal-CC with ImageJ (n= 4 independent fields; Holm–Sidak t test statistical analysis). *p= 0.024; **p= 0.0027. fMean percentage of fluorescent area
± sd for LAMP-1 in PANC185 and PANCA6L Gluc-CC and Gal-CC, using ImageJ (n= 4 independent fields; Holm–Sidak t test statistical analysis). **p=
0.00107; ***p= 0.00038. g WB analysis of LC3BI/II in Gluc-CC and Gal-CC PDAC cultures. GAPDH was used as loading control. h Densitometric
quantification of LC3BII expression in g, normalized to GAPDH levels and expressed as relative values for each tumor or pooled samples from the same
immunoblot (n= 4 biological replicates in Pool; Holm–Sidak t test statistical analysis). *p= 0.041. i RT-qPCR analysis of relative mRNA expression levels of
ATG5 in Gluc-CC and Gal-CC PDAC cultures. mRNA expression levels for each target gene are normalized to β-actin levels (n= 3 biological replicates per
tumor, n= 12 for pool; Holm–Sidak t test statistical analysis). Data are presented as mean fold change ± sd. Gluc was set as 1.0. ***p= 0.00002; **p=
0.0016; **p= 0.00105; ***p= 0.000088; ***p= 0.000029. j WB analysis of LC3BI/II in Gluc-CC and Gal-CC untreated (Gluc, Gal) or treated with the
autophagy inhibitor (Baf= Bafilomycin). GAPDH was used as loading control. k Mean fold change ± sd of densitometric quantification of autophagic flux
(LC3B-II accumulation after autophagy inhibitor addition, subtracting their respective control expression levels), (n= 4 independent immunoblots for each
culture; n= 8 pooled values, Holm–Sidak t test statistical analysis). Gluc was set as 1.0. **p= 0.0077; **p= 0.0012; ***p= 0.000022.
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concentrations of 2, 100, and 10 nM, respectively, and 0.1 µM for Mitotracker
Green FM and NAO. Fluorescence was detected using the filters RL1
(allophycocyanin), YL1 (PE), and BL1 (FITC). MitoSOX (Cat no. M36008,
Invitrogen) was used at 5 µM for 30 min at 37 °C and detected with laser YL1 (PE).
MitoBlue (kindly provided by Dr. JL Mascareñas, Universidad de Santiago de
Compostela) was used at 10 µM for 20 min at 37 °C and detected with laser VL2.
Data were analyzed with the FlowJo 9.3 software (Tree Star Inc., Ashland, OR).
Cell cycle analysis. One million cells were plated in 100 mm tissue-culture dishes,
and after 24 h, their cell cycles were synchronized using serum-free medium.
Twenty-four hours later, treatments with glucose and galactose media were initi-
ated and cell cycle was determined 6 days later. Cells were trypsinized and fixed in
cold 70% ethanol and stored at −20 °C. After 24 h, cells were incubated with 100
µg/ml RNAase A (Sigma) in PBS during 30 min at 37 °C and then stained with 50
µg/ml of PI solution (Cat no. P4864, Sigma) and stored overnight at 4 °C.
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Approximately 20,000 cells/sample were analyzed using an Attune NxT Acoustic
Cytometer (Thermo Fisher Scientific) with excitation at 561 nm and emission at
615 nm. The percentage of cells in each phase of the cell cycle was determined
using the FlowJo 9.3 software (Tree Star Inc., Ashland, OR).
WB analysis. Cells were harvested in RIPA buffer (Cat no. R0278, Sigma) sup-
plemented with protease inhibitor cocktail (Roche Applied Science, Indianapolis,
IN). Fifty micrograms of protein were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride
(PVDF) membranes (Amersham Pharmacia, Piscataway, NJ). Membranes were
sequentially blocked with 1× TBS containing 5% bovine serum albumin (BSA; w/v)
and 0.1% Tween20 (v/v), incubated with a 1:1000 dilution of the indicated anti-
bodies (Supplementary Table 1) overnight at 4 °C, washed 3 times with 1× PBS
containing 0.05% Tween20 (v/v), incubated with horseradish peroxidase-
conjugated donkey anti-rabbit or sheep anti-mouse antibody (Amersham), and
washed again to remove unbound antibody. Bound antibody complexes were
detected with SuperSignal chemiluminescent substrate (Amersham) with a MyECL
Imager (Thermo Fisher Scientific). Uncropped and unprocessed scans of all the
main blots presented can be found in the Source data file.
Sphere-formation assay. PDAC spheres were generated and expanded in
DMEM-F12 (Invitrogen) supplemented with B-27 (Cat no. A3582801, GIBCO)
and basic fibroblast growth factor (PeproTech EC). One thousand cells/ml/well
were seeded in ultra-low attachment 24-well plates (Corning) as described pre-
viously48. For serial passaging, spheres were harvested at day 7 using a 40-µm cell
strainer, dissociated to single cells with trypsin, and then re-grown in the same
conditions for 7 days (14 days total). Numbers of spheres were determined by
microscopy using an inverted EVOS FL microscope (Thermo Fisher Scientific)
using a ×10 objective with phase contrast.
RNA extraction and reverse transcriptase quantitative PCR (RT-qPCR). RNA
was isolated by using the standard protocol of the guanidine thiocyanate (GTC)
method49. One microgram of purified RNA was used for the synthesis of cDNA
using the Thermo Scientific Maxima First Strand cDNA Synthesis Kit (Cat no.
K1672, Thermo Fisher Scientific) according to the manufacturer’s instructions,
followed by RT-qPCR analysis using SYBR green and a StepOne Plus real-time
thermo-cycler (Applied Biosystems). The thermal cycle consisted of an initial
denaturation step of 10 min at 95 °C followed by 40 cycles of denaturation (15 s at
95 °C) and annealing (1 min at 60 °C). The results obtained for each gene were
normalized with the β-actin levels. For primers used, see Supplementary Table 2.
Lentivirus production and cell transduction. Lentiviral particles were produced
by co-transfection of 293T cells (kindly provided by Dr. Amparo Cano, Uni-
versidad Autónoma de Madrid, Spain) with the indicated plasmids using the
polyethylenimine-based transfection method. Briefly, 5 × 106 293T cells were co-
transfected with 1 μg packaging plasmid psPAX2, 1 μg envelope plasmid VSVG,
and 2 μg of H2B-mCherry or the NANOG reporter lentiviral vector backbone (the
sequence of the construct has been previously described in the publication by Hotta
et al.50). After 8 h, the transfection medium was changed and recombinant lenti-
viruses were harvested 48 and 72 h later. The virus particle-containing supernatant
was filtered through 0.45-µm PVDF membrane filters and aliquoted and stored at
−80 °C until needed. For lentivirus transduction, PDAC cells were seeded in 6-well
plates at a concentration of 3–5 × 104 cells/well. One milliliter of virus was directly
overlaid on cells and polybrene (Cat no. 638133, Sigma) was added at a final
concentration of 8 μg/ml. After 16 h, medium was changed. Stably transduced cells
were obtained after mCherry-positive or YFP-positive cell sorting using a FACS
Vantage SE Flow Cytometer and analyzed by the BD FACSDiva software (BD
Biosciences).
Electron microscopy. After sorting cells for the indicated markers, cells were
centrifuged and pellets were fixed with 0.1 M cacodylate buffer with a pH of 7.4 at
RT and sections were processed by the UAM Electron Microscopy unit per stan-
dard protocols. Pictures were taken with a JEM-1010 transmission electron
microscope (JEOL, USA) and analyzed by Adobe PhotoShop CS4 EXTENDED
V11.0 (Adobe Systems, USA).
Optical microscopy. All the samples processed for optical microscopy were
visualized and photographed with an Axiovert 135 TV microscope (ZEISS, Ger-
many) equipped with an Olympus DP50 digital camera and a fluorescence lamp.
The images were obtained with the program ViewFinderTM 7.1 (Better Light, USA)
and processed with the program Adobe PhotoShop CS4 EXTENDED V11.0
(Adobe systems, USA).
Real-time proliferation assay. Fifty thousand PDAC cells were seeded in a 96-
well plate. After 24 h, cells were cultured with glucose or galactose media for
14 days. Real-time analysis of proliferation and autofluorescence was performed by
IncuCyte® Zoom System (ESSEN BioScience, USA) taking images every 30 min for
40 h. The results were analyzed with the IncuCyte Zoom 2015A software (ESSEN
BioScience, USA).
Fluorescence microscopy. Non-sorted and sorted cells cultured with glucose or
galactose were seeded in 24-well culture dishes (Corning) and incubated at 37 °C.
The mitochondrial probes MitoTracker DeepRed and MitoTracker CMXRos were
added at 2 and 10 nM, respectively, for 30 min at 37 °C (all from Invitrogen),
followed by two washes with 1× PBS, and a final 5 min incubation with DAPI (2
mg/ml, Sigma). MitoTracker DeepRed was excited at 644 nm and the fluorescence
emitted was detected at 665 nm (far red fluorescence) and assigned red fluores-
cence. MitoTracker CMXRos was excited at 579 nm and the fluorescence emitted
was detected at 599 nm and assigned green fluorescence. For IF assays, cells were
fixed with 4% PFA in PBS for 20 min at RT, washed with PBS, permeabilized with
1% Triton X-100 in PBS for 15 min, blocked with 1% BSA in PBS for 1 h at RT, and
then incubated with specific antibodies (Supplementary Table 1) in a solution of
1% BSA in PBS. ProLong® Gold Antifade Reagent with DAPI (Cat no. P36941) was
then added to mark cell nuclei. The fluorescent images were collected with a laser
scanning confocal microscope Zeiss 710 and analyzed using the software Zen2009
5.5 (Oberkochen, Germany).
In vivo assays. For in vivo tumorigenicity assays, serial dilutions of Gluc-CC and
Gal-CC resuspended in MatrigelTM (Cat no. 356234, Corning) were sub-
cutaneously injected into 8-week-old female nude mice (Hsd:Athymic Nude-
Fig. 6 Immune evasion properties are enriched in Gal-CC. a Representative flow cytometric plots of the percentage of cells positive for each marker.
b Mean fold change ± sd of the different markers (n= 6 biological replicates; Holm–Sidak t test statistical analysis). Gluc was set as 1.0. **p= 0.0022;
***p < 0.000001; **p= 0.0058; ***p= 0.00002; ***p < 0.000001. c RT-qPCR analysis of relative mRNA expression levels of different EMT-related genes.
Levels were normalized to β-actin (n= 8 biological replicates; Holm–Sidak t test statistical analysis). Data are presented as mean fold change ± sd. Gluc
was set as 1.0. ns= 0.157; ***p= 0.0007; **p= 0.0038; ns= 0.229; ***p= 0.000057. dMean absorbance levels ± sd of secreted TGFβ levels, normalized
to total protein levels (n= 6 biological replicates for each culture; Holm–Sidak t test statistical analysis). *p= 0.0113; *p= 0.0164; **p= 0.046; ***p=
0.00065. e RT-qPCR analysis of relative NF-κB mRNA expression levels, normalized to β-actin (n= 4 biological replicates for each culture; Holm–Sidak
t test statistical analysis). Data are presented as mean fold change ± sd. Gluc was set as 1.0. ***p= 0.000017; ***p= 0.00027; ***p= 0.000002; ***p=
0.000073. f Semi-quantification of the profile of cytokine secretion by pixel density of duplicated spots per sample. g, h Mean arbitrary units ± sd of
secreted cytokines or inflammatory-related factors with significant changes in Gluc-CC versus Gal-CC, normalized to positive control (CTR+) (n= 4
biological replicates; Holm–Sidak t test statistical analysis). For g: ***p= 0.000053; **p= 0.0045; **p= 0.0096; **p= 0.0015. For h: **p= 0.0013; **p=
0.0017; **p= 0.005; **p= 0.0058. i Representative scheme of phagocytosis assay. Schemes were constructed using unmodified images from Servier
Medical Art by Servier, licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/legalcode).
j Representative flow cytometric dot plots demonstrating DilC-stained macrophages and PKH67-stained Gluc-CC or Gal-CC. DilC+PKH67+ double-
positive cells represent phagocytosis. k Mean fold change ± sd of the DilC+PKH67+ double-positive population in the phagocytosis assay using monocyte-
derived macrophages from 3 different healthy donors (n= 4 biological replicates for each condition; two-way ANOVA statistical analysis). ***p < 0.0001;
*p= 0.047; ns= 0.651; **p= 0.0016; *p= 0.019; *p= 0.018; ns= 0.652; **= 0.0095; ns= 0.988. l–n Mean fold change ± sd in cell death after 10 days
co-cultivating PDAC cells with activated T cells isolated from healthy l Donor 1, m Donor 2, or n Donor 3 (n= 4 biological replicates per condition;
Holm–Sidak t test statistical analysis), (red line= Control, basal toxicity set as 1.0). For l: ***p= 0.000016; ***p= 0.00075; **p= 0.0013. For m: ***p=
0.000002; ***p= 0.00025; ***p < 0.000001. For n: ***p < 0.000001; ***p= 0.00018; **p= 0.0023.
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Foxn1nu/Foxn1+; Envigo) and tracked for 10–14 weeks for tumor formation. If a
mouse in a specific dilution group warranted sacrifice, all of the mice (Gluc-CC and
Gal-CC) in that dilution group were sacrificed in order to obtain the number of
tumors for all mice at the exact same time. For the dilutions 50,000, 10,000 and
5000, mice were sacrificed at 10 weeks post inoculation. For the 1000-cell dilution
group, mice were sacrificed at 14 weeks post inoculation. CSC frequencies were
calculated using the ELDA software (http://bioinf.wehi.edu.au/software/elda/). For
in vivo tail vein injection invasion assays, 8-week-old NOD-SCID mice (Instituto
de Investigaciones Biomédicas “Alberto Sols” CSIC-UAM) were injected intrave-
nously via the tail vein with either 5 × 105 mCherry-H2B-labeled PANC185scd or
PANCA6L Gluc-CC or Gal-CC (resuspended in 0.9% physiological saline solution)
using a 27-G needle. The mice were sacrificed 10 dpi or 3 months pi. Indicated
organs were collected, digested, and stained with antibodies to detect TAMs
(CD45+CD11b+F4-80+) (Supplementary Table 1). In parallel, the percentage of
mCherry+ cells present in each organ was determined by FACS using an Attune
NxT Acoustic Cytometer (Thermo Fisher Scientific). The percentage of cells was
determined using the FlowJo 9.3 software (Tree Star Inc., Ashland, OR). Organs
were also analyzed by IVIS-Lumina II (Caliper Life Sciences, Hopkinton, MA,
USA) and analyzed by the software Living image 3.2 (Perkin Elmer, Waltham,
MA, USA).
For all in vivo experiments, mice were housed according to institutional
guidelines and all experimental procedures were performed in compliance with the
institutional guidelines for the welfare of experimental animals approved by the
Universidad Autónoma de Madrid Ethics Committee (CEI 60-1057-A068 and CEI
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103-1958-A337) and La Comunidad de Madrid (PROEX 335/14 and PROEX 294/
19) and in accordance with the guidelines for Ethical Conduct in the Care and Use
of Animals as stated in The International Guiding Principles for Biomedical
Research involving Animals, developed by the Council for International
Organizations of Medical Sciences (CIOMS). Briefly, mice were housed according
to the following guidelines: a 12-h light/12-h dark cycle, with no access during the
dark cycle; temperatures of 65–75 °F (~18–23 °C) with 40–60% humidity; a
standard diet with fat content ranging from 4–11%; sterilized water was accessible
at all times; for handling, mice were manipulated gently and as little as possible;
noises, vibrations, and odors were minimized to prevent stress and decreased
breeding performance; and enrichment was always used per the facility’s guidelines
to help alleviate stress.
Immunohistochemistry. For histopathological analysis, 3-μm sections of formalin-
fixed paraffin-embedded blocks were used for IHC analysis of human cytokeratin
19 using the primary and secondary antibodies and dilutions detailed in Supple-
mentary Table 1. Antigens were visualized using 3,3-diaminobenzidine tetra-
hydrochloride plus (DAB+). Counterstaining was performed with hematoxylin.
Digital images were obtained using an Axiophot (Carl Zeiss) microscope with a
×10 objective and DP70 Olympus camera. Images were processed using the ImageJ
v2.0.0 software (NIH, USA, http://rsbweb.nih.gov/ij/).
Autophagy flux assay. For autophagy flux analysis, Gluc-CC and Gal-CC were
treated with the lysosomotropic reagent Bafilomycin A1 at a concentration of 150
nM (Calbiochem, Thermo Fisher Scientific, Waltham, MA, USA) for 5 h. After
treatment, Gluc-CC and Gal-CC were harvested and analyzed by WB as described
above. For densitometry, WB images were analyzed using PhotoShop CS4
EXTENDED V11.0 (Adobe Systems, USA). Autophagy flux compares the LC3B-II
(Sigma Aldrich, St. Louis, MO, USA) levels with and without the autophagy
inhibitor and is calculated as the ratio of LC3B-II in the presence and absence of
the autophagy inhibitor compared to the control condition (Gal-CC versus Gluc-
CC). The data were normalized to the indicated housekeeping protein.
Quiescence assay. Gluc-CC and Gal-CC were labeled with PKH26 red fluorescent
cell membrane labeling dye (Cat no. MINI26-1KT, Sigma) according to the
manufacturer’s instructions. At the indicated days post staining, for a total of
14 days, cells were trypsinized, washed, and the percentage of PKH26+ cells was
determined using an Attune NxT Acoustic Cytometer (Thermo Fisher Scientific).
DAPI (Sigma) was used to exclude dead cells with laser VL1.
Senescence assay. β-Galactosidase activity was measured in Gluc-CC y Gal-CC
according to the manufacturer’s instructions (Cat no. 94433, Sigma). β-
Galactosidase+ cells were determined using an Axiovert 135 TV optical microscope
(ZEISS, Germany), and the ImageJ 2.0.0 software (NIH, USA) was used for further
analysis.
Chemoresistance in vitro assays. PDAC cells were seeded in a 12-well plate at
106 cells/well. Following 14 days of culture with glucose or galactose, Gal-CC or
Gluc-CC cells were treated with 1 μg/ml of GEM, 3 µM of MTX, or 1 µM of DXR
for 2 days. After 2 days, drugs were removed and PDAC cells were allowed to
recover for 3 days. For metabolic drugs, Gluc-CC and Gal-CC were treated with 5
µM of Menadione, 10 nM of Rotenone, 100 µM of Resveratrol, 3 mM of Metfor-
min, or 5 mM of 2-DG for 3 days. Following treatments, the supernatant was
collected, and the ToxiLight™ Bioassay Kit (Cat no. LT07-217, Lonza, Switzerland)
was used to evaluate the toxicity using a bioluminescence GLOMAX Luminometer
(Promega).
Measurement of mitochondrial metabolism by Seahorse analyzer. Measure-
ments of OCR were performed with a XF extracellular flux analyzer (Seahorse
Bioscience, Agilent Technologies, Santa Clara, CA, USA), and data were collected
with the XF96 1.4.2 Software (Agilent). Briefly, 14-day-old Gal-CC or Gluc-CC
were trypsinized and re-seeded at a density of 105 cells per well in a XF24 cell
culture microplate with DMEM (4.5 g/L glucose, +L-Glutamine, -Pyruvate, pH 7.6
at RT) supplemented with 10% heat-inactivated FBS (Gibco) and 1% Pen/Strep. On
the day of the assay (24 h after re-seeding), medium was changed to non-
carbonated Seahorse measurement medium and the XF24 plate was transferred to a
temperature-controlled (37 °C) XF24 Extracellular Flux analyzer and equilibrated
for 10 min. To determine the basal respiration, four assay cycles (1-min mix, 2-min
wait, and 3-min measuring period) were performed. Then oligomycin (4 μM) was
added by automatic pneumatic injection (three assay cycles) to inhibit ATP syn-
thase and thus approximate the proportion of respiration used to drive ATP
synthesis versus proton leak-linked respiration. Oligomycin was followed by an
injection of FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) (0.5
μM) to completely dissipate proton motive force and maximally stimulate mito-
chondrial respiration (three assay cycles), thus determining SRC and substrate
oxidation capacity. An injection of rotenone (4 μM) and antimycin A (2 μM) was
used to correct for the non-mitochondrial respiration rate (three assay cycles),
which was subtracted from all the other rates. Basal respiration was calculated as
the oligomycin-sensitive fraction of mitochondrial respiratory activity, estimating
the proportion of basal respiration used to drive ATP synthesis. To determine
ECARs, experiments were terminated by injection of 2-DG (100 mM), correcting
for non-glycolytic acidification. Injection of 2-DG enables the calculation of gly-
colytic acidification. Data obtained after oligomycin treatment induced glycolytic
capacity. Raw data were normalized to total cell numbers, determined by optical
absorbance of lysed crystal violet-stained cells.
RNA sequencing analysis. Total RNA was isolated by the GTC method using
standard protocols49. Sequencing libraries were prepared with the “NEBNext Ultra
II Directional RNA Library Prep Kit for Illumina” (NEB no. E7760) as recom-
mended by the kit manufacturer. Briefly, polyA+ fraction was purified and ran-
domly fragmented, converted to double-stranded cDNA, and processed through
subsequent enzymatic treatments of end-repair, dA-tailing, and ligation to adap-
ters. Adapter-ligated library was completed by PCR with Illumina PE primers. The
resulting purified cDNA libraries were applied to an Illumina flow cell for cluster
generation and sequenced on an Illumina NextSeq 550 (with v2.5 reagent kits),
according to the manufacturer’s protocols. RNAseq data sets were analyzed using
the tool Nextpresso51. Nextpresso is comprised of four basic levels: (1) quality
check, (2) read cleaning and/or down-sampling, (3) alignment, and (4) analysis
(gene/isoform expression quantification, differential expression, gene set enrich-
ment analysis, and fusion prediction). The gene signatures (Hallmark genesets, h.
all.v7.1.symbold.gmt) from GSEA—Molecular Signature Database for Gene set
enrichment analysis was used for pathway enrichment analysis with GSEA v4.0.3
(Broad Institute).
Zebrafish maintenance and xenograft assays. Zebrafish embryos were obtained
by mating adult zebrafish (Danio rerio, wild type), maintained in 30-l tanks with a
ratio of 1 fish per liter of water, with 14 h/10 h light/dark cycle and a temperature of
Fig. 7 In vivo immune evasion and metastasis are upregulated in Gal-CC. a Representative images of zebrafish embryo tails at 1, 4, and 6 days post-
injection (dpi). Scale bar= 250 µM. b Mean ± sem of the integrated density (fluorescence measured) 1 dpi (biological replicates: n= 29 for Glucose and
n= 36 for Galactose; Student’s t test) **p= 0.0025. c, d Mean ± sem of proliferation ratio observed between Gluc-CC and Gal-CC at c 4 dpi and d 6 dpi.
Proliferation ratios are represented in comparison to 1 dpi (red line) (biological replicates: 4 dpi: n= 26 for Glucose and n= 14 for Galactose; Student’s
t test; **p= 0.0021; 6 dpi: n= 18 for Glucose and n= 11 for Galactose; Student’s t test; **p= 0.0019). e Representative in vivo invasion assay scheme.
Schemes were constructed using unmodified images from Servier Medical Art by Servier, licensed under a Creative Commons Attribution 3.0 Unported
License (https://creativecommons.org/licenses/by/3.0/legalcode). f, gMean fold change ± sem of mCherry+ cells present in different organs analyzed at
f short time (10 days post-injection), (n= 2 independent experiments with a total of n= 17 mice; Holm–Sidak t test statistical analysis) or at g long time
(3 months post-injection). Number (n) of samples analyzed are indicated for each organ. (n= 1 independent experiment with a total of n= 6 mice;
Holm–Sidak t test statistical analysis). For f: ns= 0.25; ns= 0.26; **p= 0.0058; ns= 0.27; **p= 0.0016. For g: *p= 0.017; *p= 0.034; *p= 0.025; *p=
0.027. h Representative fluorescent IVIS images of different organs from mice at 3 months post-injection. i Mean ± sem of total radiant efficiency [p/s]/
[µW/cm2] of different organs from h. Number (n) of samples analyzed are indicated for each organ. (n= 1 independent experiment with a total of n= 6
mice; Holm–Sidak t test statistical analysis). All data are not statistically significant. j, k Mean fold change ± sem of the CD45+CD11b+F4-80+ population
present in the different organs analyzed at j short time (n= 2 independent experiments with a total of n= 17 mice; Holm–Sidak t test statistical analysis) or
at k long time (n= 1 independent experiment with a total of n= 6 mice; Holm–Sidak t test statistical analysis). Red lines indicate baseline levels of the
CD45+CD11b+F4-80+ population of control mice (n= 6), set as 1.0. Number (n) of samples analyzed for Gluc-CC- and Gal-CC-injected mice are indicated
for each organ. For j: ns= 0.609; ***p= 0.000003; ***p= 0.00057; ns= 0.738. For k: *p= 0.0361; *p= 0.033; *p= 0.0362; ns= 0.982.
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28.5 °C according to published procedures35. All the procedures used in the
experiments as well as fish care were performed in agreement with the Animal Care
and Use Committee of the University of Santiago de Compostela and the standard
protocols of Spain (Directive 2012-63-UE). At the final point of the experiments,
zebrafish embryos were euthanized by tricaine overdose.
For zebrafish xenograft assays and image analysis, zebrafish embryos were
collected at 0 h post-fertilization (hpf) and incubated until 48 hpf at 28.5 °C. At 48
hpf, hatched embryos were anesthetized with 0.003% of tricaine (Sigma). mCherry-
H2B-labeled PANC185scd and PANCA6L Gluc-CC and Gal-CC were trypsinized,
resuspended, and concentrated in an Eppendorf at 106 cells per tube for each
condition. Cells were then resuspended in 10 µl of PBS with 2%
polyvinylpyrrolidone to avoid cellular aggregation. Borosilicate needles (1 mm O.
D. × 0.75 mm I.D.; World Precision Instruments) were used to perform the
xenograft assays in the zebrafish embryos. Between 100 and 150 cells were injected
into the circulation of each fish (Duct of Cuvier) using a microinjector (IM-31
Electric Microinjector, Narishige) with an output pressure of 34 kPA and 30 ms of
injection time per injection. Subsequently, the injected embryos were incubated at a
temperature of 34 °C for 6 dpi in 30 ml Petri dishes for each condition with salt
dechlorinate tap water. Imaging of the injected embryos was performed using a
fluorescence stereomicroscope (AZ-100, Nikon) at 1, 4, and 6 dpi in order to
measure the proliferation of the PANC185scd- and PANCA6L-injected human
cancer cells inside the zebrafish circulation in each of the conditions assayed.
The image analysis of the injected embryos was carried out using the Quantifish
software v2.1 (University College London, London, UK) in order to obtain the
proliferation ratio of the cells in the region of the caudal hematopoietic tissue of the
embryos, where the cells proliferate and metastasize. This program measures in
each of the images provided the intensity of the fluorescence and the area of the
positive pixel above a certain threshold of the cells. With these parameters, an
integrated density value is obtained allowing the researcher to compare different
times between images to reach a proliferation ratio.
Lactate production assay. Supernatant from Glu-CC and Gal-CC were collected
to evaluate the changes in the levels of lactate production. The analysis was per-
formed using the Lactate Assay Kit (Sigma Aldrich, St. Louis, MO, USA) according
to the manufacturer’s instructions. The optical density was determined using a
Synergy™ HT Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA) at a
wavelength set to 570 nm.
ATP determination assay. Lysate pellets of cells from Glu-CC and Gal-CC were
collected to evaluate the changes in the levels of ATP. The analysis was performed
using the Molecular Probes ATP Determination Kit (Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s instructions. Biolumines-
cence was determined using a Synergy™ HT Multi-Mode Microplate Reader
(BioTek, Winooski, VT, USA).
Isolation of macrophages and T cells from human blood. Blood samples from
healthy donors were provided by the BioBank Hospital Ramón y Cajal-IRYCIS
(PT13/0010/0002), integrated in the Spanish National Biobanks Network (ISCIII
Biobank Register No. B.0000678). Samples were processed following standard
operating procedures with the appropriate approval of the Hospital Ramón y Cajal
Ethical and Scientific Committee (Control No.: DE-BIOB-73 AC65, RG.BIOB-57,
and RG.BIOB-54), with informed consent and according to Declaration of Helsinki
principles. Blood samples were diluted with PBS (Cat no. 10010023, Gibco) and
Ficoll (Cat no. L6115, Merck) was used to isolate peripheral blood mononuclear
cells (PBMCs). PBMCs were divided across three 6-well culture plates (per donor)
with RPMI 1640 media containing 10% FBS and 50 units/ml penicillin/strepto-
mycin. After 24 h, monocytes adhered to the plate surface were separated from the
lymphocytes that remain in suspension and that were seeded in T-75 flasks for
their subsequent activation and growth.
Cytokine array. Changes in protein levels related to immune evasion processes
were determined by measuring changes in the levels of cytokines or inflammatory-
related molecules released into the culture medium by Gluc-CC and Gal-CC cells,
using the Proteome Profiler Human Cytokine Array Kit (R&D Systems, Minnea-
polis, MN, USA), according to the manufacturer’s instructions. Cytokine array
images were obtained using the MyECL Imager (Thermo Fisher Scientific). For
densitometry analysis, array images were analyzed using PhotoShop CS4
EXTENDED V11.0 (Adobe Systems, USA). Data were normalized to the indicated
array positive control.
TFGβ secretion assay. Culture medium from Gluc-CC and Gal-CC were collected
to evaluate the changes in the levels of TGFβ secretion. The analysis was performed
using the Human TGFβ1 Immunoassay Quantikine ELISA Kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s instructions. The optical
density was determined using a Synergy™ HT Multi-Mode Microplate Reader
(BioTek, Winooski, VT, USA) at a wavelength set to 450 nm.
Macrophage immunoevasion assay. Five days after isolation of macrophages
from the blood of healthy donors (see above), macrophages were labeled with the
red membrane dye DilC, according to the manufacturer’s instructions (Cat no.
D3911, Thermo Fisher). Gluc-CC and Gal-CC were harvested and labeled with
PKH67 green fluorescent cell membrane labeling dye (Sigma) according to the
manufacturer’s instructions. Labeled cells were seeded together with labeled mac-
rophages during 24 h. Afterwards, macrophage-mediated phagocytosis (DilC
+/PKH67+ cell percentages) was determined using the AttuneNxT cytometer
(Thermo Fisher Scientific), and data were analyzed with the FlowJo 9.3 software
(TreeStar, Ashland, OR).
T cell immunoevasion assay. Seven days after isolation and expansion of T cells
from the blood of healthy donors, T cells were activated with phytohemagglutinin-
P (Cat no. L8754, Merck) at a concentration of 5 μg/ml and with 20 ng/ml of
human rIL-2 (Cat no. PHC0026, Gibco) for 7 days. Gluc-CC and Gal-CC were
harvested and co-seeded with activated T cells during 10 days. Afterwards, T cells
were removed and the extent of cytotoxicity was determined with the ToxiLight™
Bioassay Kit (Cat no. LT07-217, Lonza, Switzerland) using a bioluminescence
GLOMAX Luminometer (Promega). The data were analyzed with the Prism
8 software (San Diego, CA).
Statistical analysis and reproducibility. Results are presented as means ± stan-
dard deviation (stdev) or ±standard error of the mean (SEM), as indicated in the
figure legends. Different two-sided statistical analyses were performed: one-way
analysis of variance (ANOVA; two sided) with Bonferroni adjustment or with an
unpaired two-tailed t test to determine significance, two-way ANOVA with Tukey’s
multiple comparisons test, or unpaired two-sided (confidence interval of 95%) t test
for multiple comparisons using the Holm–Sidak method were used to determine
differences between means of groups. p Values < 0.05 were considered statistically
significant. GraphPad software (GraphPad Prism 8.0, GraphPad Software, La Jolla,
CA, USA) was used to perform the statistical analysis of the data.
The number of biologically independent samples are indicated in the figure
legends. Repeated independent experiments per each panel with similar results are
shown below. n= 1 (Figs. 1a, e, 2b, 3d, l, 4a, k, 5c, k, 6e, n, 7g, k and Supplementary
Figs. 1a, c, h, i, 2a–e, h–j, m, 4a, b, 3e, 5a, d–f, 6a, b, 7a–d); n= 2 (Figs. 1f, g, 2e–j, l,
m, 3e, 5a, 6c, d, 7f, j and Supplementary Figs. 2a–e, g, 3b, d, 5b, h–k); n= 3
(Figs. 2f, 6b, 7b, d and Supplementary Figs. 1f, 3i, 6d–f), n= 4 (Figs. 2d, 3b and
Supplementary Figs. 1b, 2f).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNAseq data from Gluc-CC and Gal-CC cells, generated in this study, have been
deposited in the ArrayExpress database52 at EMBL-EBI (www.ebi.ac.uk/arrayexpress)
under accession number E-MTAB-9483. Source data are provided with this paper.
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